GeoVax is a clinical-stage biotechnology company developing vaccines to combat HIV/AIDS. Our unique, proprietary vaccines are designed for the predominant HIV virus subtypes in the Americas and Europe. The vaccine expresses non-infectious virus like particles in the person being vaccinated using a recombinant DNA for priming and a recombinant poxvirus for boosting the vaccine response. The GeoVax vaccines are being tested in human clinical trials to (a) prevent HIV infection and (b) to serve as an immunotherapy for individuals who are already infected with HIV.
As a leader in our field, we are committed to progress against the most devastating global disease of our lifetime.
We know that an HIV vaccine could save millions of lives and dramatically redirect the focus of healthcare worldwide. Each year, over $22 billion is spent responding to the AIDS epidemic across the globe. Twice as much of this expenditure go to treatment than to prevention. A preventive HIV vaccine could free both human and financial resources for other world needs. An immunotherapy solution could transform the lives of millions of people and revolutionize the legacy of HIV for all who have suffered because of it.We know our work could affect the lives of millions worldwide, and we invite you to join our effort.